Kornimate/medical-research-clean huggingface dataset:
clinical relevance of thoracic echography for the early diagnosis of interstitial lung disease in systemic scleroderma - pilot study

Conditions: Systemic Sclerosis

Summary: diffuse interstitial lung disease (pid) is the leading cause of death in systemic scleroderma (ssc). major progress has recently been made in its therapeutic management. early diagnosis is essential to optimize this management. current diagnostic techniques are based on high-resolution computed tomography on the thorax (hrct) and pulmonary functional tests (pft). however, these explorations have their limitations. thus, there is a need for new techniques for a very early diagnosis of pid-ssc. thoracic ultrasound (tus) is an innovative, easily accessible, non-irradiating, inexpensive and painless tool. it is an emerging technique for the diagnosis of pid and has already proven its sensitivity for the detection of interstitial damage, as defined by hrct. the main objective of the precoss study is to describe the prevalence of an ultrasound interstitial syndrome in patients with ssc, free of pid-ssc (defined by the goh criteria) detectable by hrct.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * diagnosis of systemic scleroderma according to eular/acr 2013 criteria * absence of diffuse interstitial lung disease proven by scanner on the day of inclusion * forced vital capacity ≥ 80% of the value predicted on the last respiratory function test performed. * carbon monoxide diffusion capacity corrected for hemoglobinemia ≥ 70% of the value predicted on the last respiratory function test performed. * patient capable of performing functional exploration during the year * affiliation to a social security system * patient who has given free and informed consent exclusion criteria: * any other connectivity associated to systemic sleroderma * any chronic pathologies, co-morbidities, history judged by the investigator as being likely to lead to complications for the patient and/or which may impact the results of functional exploration during exercise. * all known fibrotic and/or obstructive respiratory pathologies. * presence of echocardiographic signs of pulmonary arterial hypertension according to 2015 criteria * diagnosis of left heart disease * cumulative smoking \> 10 packs.years * infectious pneumonia within 90 days prior to inclusion * acute respiratory illness requiring hospitalization within one year prior to inclusion * pregnant or breastfeeding woman * refusal to participate in the study * refusal to use the data * adults under legal protection (temporary protection measure, curatorship, guardianship)
minimally invasive surgical management of traumatic spinopelvic instability

Conditions: SPINAL Fracture

Summary: the main aim of this study is to evaluate the results of performing minimally invasive surgical management for cases with traumatic spinopelvic instability and spinopelvic dissociation. this will include using percutaneous pedicle and s2 alar iliac screws, minimally invasive transforaminal lumbar interbody fusion and transtubular posterior decompression.

study procedure: 1. patient enrollment and pre-operative evaluation: upon arrival, the patient will be managed in the emergency department according to the advanced trauma life support (atls) protocol. after achieving the haemodynamic stability, in cases of shock, x-rays (ap and lateral view of the lumbosacral region, inlet and outlet views of the pelvis) and ct scan of the pelvis will be performed. if the fracture pattern fits the inclusion criteria, the patient will be offered to enroll in the study and the patient will be prepared for surgery. 2. surgery: the surgery will be performed under general anaesthesia and fluoroscopic guidance. the patients will be positioned prone on an open top of a radiolucent table with large bumps under the thighs to accentuate an extension force on the legs which will be the main reduction maneuver in the surgical procedure. bilateral percutaneous l4 and l5 pedicle screws will be placed under fluoroscopic guidance with jamshidi needles, and these were will also be used the iliac fixation via percutaneous s2 alar iliac screws. cases presenting with significant instability, minimally invasive transforaminal lumbar interbody fusion (mis-tlif) will be performed. additionally, in cases with neurological deficit, posterior decompression will be performed. 3. follow-up the patient will have four follow up visits (one and half month, 3month, 6month and 1 year) besides the discharge visit, during which the functional outcome scores will be filled out. ap and lateral view pelvis x-rays will be performed every visit. ct scan, ap and lateral scanograms will be only performed on the 1-year visit.

Eligibility criteria:
inclusion criteria: skeletally mature patients presenting with sacral fractures (provided that the fracture line passes below the level of s2) associated with lumbosacral instability showing one of the following: 1. unilateral or bilateral l5-s1 facet fractures (ao classification type c1 and c2) 2. spinopelvic dissociation (ao type c3) 3. traumatic lumbosacral dislocation exclusion criteria: 1. unwillingness to participate in the study 2. pathological fractures 3. other medical comorbidities that preclude surgical intervention.

Keywords: spinopelvic instability spinoplevic dissociation spinopelvic fixation lumbopelvic fixation
study of the bite® blinatumomab (mt103) in adult patients with relapsed/refractory b-precursor acute lymphoblastic leukemia (all)

Conditions: B-ALL

Summary: the purpose of this study is to determine whether the bispecific t-cell engager blinatumomab is effective, safe and tolerable in the treatment of patients with relapsed/refractory b-precursor all.

relapsed/refractory b-precursor all in adult patients is an aggressive malignant disease with dismal prognosis and unmet medical need. additional therapeutic approaches are urgently needed. blinatumomab is a bispecific single-chain antibody construct designed to link b cells and t cells resulting in t cell activation and a cytotoxic t cell response against cd19 expressing cells. the purpose of this study is to investigate the efficacy, safety and tolerability of different doses of the bispecific t-cell engager blinatumomab in adult patients with relapsed/refractory b-precursor all. patrticipants will receive up to five 4-week cycles of intravenous blinatumomab treatment.

Eligibility criteria:
inclusion criteria: * patients with b-precursor all relapsed after at least induction and consolidation or having refractory disease * more than 5% blasts in bone marrow * eastern cooperative oncology group (ecog) performance status ≤ 2 * life expectancy of ≥ 12 weeks exclusion criteria: * history or presence of clinically relevant central nervous system (cns) pathology * infiltration of cerebrospinal fluid (csf) by all * autologous/allogeneic hematopoietic stem cell transplantation (hsct) within six weeks/three months prior to start of blinatumomab treatment * active graft-versus-host disease (gvhd) * patients with philadelphia chromosome (ph)+ all eligible for treatment with dasatinib or imatinib * cancer chemotherapy within two weeks prior to start of blinatumomab treatment * immunotherapy (e.g. rituximab) within four weeks prior to start of blinatumomab treatment * infection with human immunodeficiency virus (hiv) or hepatitis b (hbsag positive) or hepatitis c virus (anti-hcv positive) * pregnant or nursing women * previous treatment with blinatumomab

Keywords: blinatumomab b-all adult all relapsed all refractory all leukemia all lymphatic diseases lymphoproliferative disorders bispecific antibody anti-cd19 immunotherapeutic treatment
trial of screening for aloa-igg atheroabzyme test

Conditions: Myocardial Ischemia; Acute Coronary Syndrome

Summary: this is a trial of screening for aloa-igg atheroabzyme test comparing healthy, asymptomatic myocardial ischemic and acute coronary syndrome patients.


Eligibility criteria:
inclusion criteria: * healthy patients * high risk patients or asymptomatic myocardial ischemic patients * acute coronary syndrome patients exclusion criteria: * none

Keywords: determination of the level of oxidised ldl by measuring the level of igg in blood
comparative study of aripiprazole and olanzapine in the treatment of patients with acute schizophrenia

Conditions: Schizophrenia

Summary: the purpose of this study is to compare the efficacy and tolerability of aripiprazole to olanzapine over 26 weeks for the treatment of schizophrenia


Eligibility criteria:
inclusion criteria: * patients with dsm-iv diagnosis of schizophrenia patients in acute relapse * treated as outpatients for at least one continuous 3-month period during the past 12 months * panss total score ≥60 * previously responsive to neuroleptics (other than clozapine) * able to give informed consent and comprehend and satisfactorily comply with the protocol requirements exclusion criteria: * an axis i (dsm-iv) diagnosis of schizoaffective disorder * a clinical picture and/or history that was consistent with: (a) delirium, dementia, amnestic or other cognitive disorders; (b) bipolar disorder; (c)personality disorder * nonresponsive to prior olanzapine therapy * likely to require prohibited concomitant therapy * dsm-iv criteria for any significant substance abuse within the past three months, including addiction to cocaine or alcohol * known to be allergic or hypersensitive to study drugs * represented a significant risk of committing suicide based on history or mental status exam * unstable thyroid pathology and treatment within the past six months * a history or evidence of a medical condition that would expose the patient to an undue risk * clinically significant abnormal laboratory test results (including urine drug screen), vital sign, or ecg findings
influence of plasma rich in growth factors (prgf) on healing of medial collateral ligament (mcl) tear

Conditions: MCL Tear

Summary: to evaluate the influence of plasma rich in growth factors (prgf) on the healing process of medial collateral ligament (mcl) tear.

autologous platelet-rich matrices may aid in the healing of ligaments \& tendons by promoting and accelerating tissue healing because of the release of growth factors including transforming growth factor (tgf)-beta1 and platelet-derived growth factor (pdgf) from platelet alpha-granules.

Eligibility criteria:
inclusion criteria: * age 18-40 years old * diagnosed mcl tear grade 2/3 exclusion criteria: * pregnancy * mental or physical disabilities
simultaneous versus staged resection for initially resectable synchronous rectal cancer liver-limited metastasis

Conditions: Rectal Neoplasm With Metastasis to the Liver

Summary: the purpose of this study is to investigate the safety and efficacy of simultaneous liver resections compared to staged hepatectomies of rectal cancer with liver metastasis and to compare the short and long-term survival between the two groups.

the optimal surgical strategy for treatment of patients with resectable synchronous rectal liver metastases remains controversial. to answer whether synchronous rectal cancer liver metastases (slm) should be resected simultaneously with primary cancer or should be delayed, we conducted a randomized, controlled trial to compare the safety and efficacy of simultaneous versus delayed resection of the rectum and liver. patients with rectal cancer and resectable slm were randomly assigned to either simultaneous or delayed resection of the metastases. the primary outcome was the rate of major complications (clavien-dindo grade≥iii) within 30 days following surgery. secondary outcomes included disease-free and overall survival. a consecutive patients of rectal cancer with liver metastasis from zhongshan hospital, fudan university were enrolled and randomly assigned to simultaneous liver resections and staged hepatectomies. post-operative complications, peri-operative mortality, long-term survival were compared.

Eligibility criteria:
inclusion criteria: * age\>=18 and \<= 75 years * resectable primary rectal tumor * remnant liver volume \>= 60% * without other organ metastasis or peritoneum metastasis * without contradiction of cardiac and pulmonary diseases * american society of anesthesiologists (asa) class i - ii * histologically proved rectal adenocarcinoma exclusion criteria: * age \> 75 years * unresectable primary rectal tumor * remnant liver volume \< 60% * with other organ metastasis or peritoneum metastasis * with contradiction of cardiac and pulmonary diseases * tumors assessed as clinical complete response after preoperative radio- or chemoradiotherapy * signs of acute intestinal obstruction, bleeding or perforation needing emergency surgery * multiple colorectal tumors or other schedules needing for synchronous colon surgery * co-existent inflammatory bowel disease * pregnancy or lactation * patients received treatment other than preoperative radio- or chemoradiotherapy

Keywords: rectal neoplasms liver metastasis surgery simultaneous resection staged resection
effect of gnrh agonist vs gnrh antagonist on oocyte morphology during ivf/icsi

Conditions: In Vitro Fertilization; Intracytoplasmic Sperm Injection; Infertility

Summary: selection of developmentally competent oocytes enhances ivf efficiency. usually, oocyte quality is determined based on its nuclear maturation and the presence of specific cytoplasmic and extracytoplasmic morphologic features. gonadotropin-releasing hormone agonists (gnrh agonists) and gonadotropin-releasing hormone antagonists (gnrh antagonists) are used during controlled ovarian stimulation (cos) protocols in order to prevent premature luteinizing hormone (lh) surge and premature ovulation. however, gnrh receptors are also expressed in extra-pituitary tissues such as ovary, but it is still unknown whether the type of gnrh analogues used during cos could affect the oocyte morphology, especially with the limited and conflicted currently available data. thus, we are conducting this prospective, non-randomised, open-label, clinical trial to compare the effects of two pituitary suppression regimens; gnrh agonist-long protocol and gnrh antagonist-flexible protocol on oocyte morphology during ivf/icsi.


Eligibility criteria:
inclusion criteria: * women undergoing ivf/icsi. * age: 18-39 years. * both ovaries present. exclusion criteria: * age ≥ 40 years * history of three or more previous ivf failures. * patients with hormonal disorders like hyperprolactinemia, thyroid disorders. * patients with polycystic ovarian syndrome. * patients who previously undergo unilateral oophorectomy. * patients with chronic diseases: diabetes mellitus, cardiovascular diseases, liver diseases, kidney diseases. * patients with diseases may affect ivf outcomes: endometriosis, uterine fibroids, hydrosalpinx, adenomyosis, autoimmune diseases, * cancer.

Keywords: gnrh agonist gnrh antagonist oocyte morphology assisted reproduction technique in vitro fertilization intracytoplasmic sperm injection
vo2peak and exercise efficiency in upper-body poling

Conditions: Spinal Cord Injuries

Summary: this study compares peak oxygen uptake (vo2peak) and exercise efficiency in upper-body poling versus arm crank ergometry in trained able-bodied and paraplegic participants.

peak oxygen uptake (vo2peak) and exercise efficiency are key factors for endurance performance. in persons who are primarily able to use their upper-body during exercise, such as many paralympic athletes, the mode most commonly used in assessing vo2peak and efficiency is arm crank ergometry (ace). however, sport-specificity of the test mode has been suggested to be of importance for achieving vo2peak and exercise efficiency that are reflective of the aerobic capacity in the respective sport. for ice sledge hockey players, cross-country sit skiers and sitting biathletes, upper-body poling (up) is the most sport-specific test mode. however, it has not yet been investigated whether vo2peak and efficiency differ between ace and up. therefore, the aim of this study was to compare vo2peak and exercise efficiency in upper-body poling versus arm crank ergometry in trained able-bodied and paraplegic participants. participants performed four 5-min submaximal stages at increasing effort and an incremental peak test to exhaustion in both ace and up.

Eligibility criteria:
inclusion criteria: * participants between the age of 18 and 50 * well upper-body-trained participants with or without paraplegia exclusion criteria: * people with injuries or sicknesses that might have impacted the testing

Keywords: oxygen consumption physical endurance
controlled trial evaluating the efficacy of protein supplementation in the short term after bariatric surgery

Conditions: Obesity

Summary: the main objective will be to evaluate the effect at 5 weeks of nutritional management associated with protein supplementation (adapted to the post-operative period) on the maintenance of lean body mass at the whole body in obese patients after a sleeve gastrectomy. secondary objectives will assess protein intake, food safety, the effect of protein supplementation on body fat in the entire body and the metabolic rate and the impact on quality of life and post-operative joint pain.

the main objective will be to evaluate the effect at 5 weeks of nutritional management associated with protein supplementation (adapted to the post-operative period) on the maintenance of lean body mass at the whole body in obese patients after a sleeve gastrectomy. secondary objectives will assess protein intake, food safety, the effect of protein supplementation on body fat in the entire body and the metabolic rate and the impact on quality of life and post-operative joint pain. there is still no study evaluating the protein supplementation adapted patients after sleeve gastrectomy on maintaining lean body mass.

Eligibility criteria:
inclusion criteria: * surgical management of sleeve gastrectomy kind exclusion criteria: * food allergies * weight\> 135 kg (maximum weight supported by the dxa) * orthopedic prosthesis (hip, knee ...) that would make it impossible to interpret the measurement of dxa * history of bariatric surgery: adjustable gastric banding, vertical banded gastrectomy ...
making sparx fly in nunavut: pilot testing an e-intervention for boosting resilience against youth depression

Conditions: Depressive Symptoms; Emotion Regulation

Summary: the goal of this pilot trial was to test sparx with inuit youth in northern canada. sparx is an educational video game designed to teach cognitive behavioural therapy strategies and techniques. this "serious game" has previously shown promise in addressing symptoms of depression with māori youth in new zealand. researchers in this study tested sparx's suitability with inuit youth in the territory of nunavut using surveys that youth completed before and after gameplay. hypothesis 1: youth who completed sparx were expected to experience a decrease in depressive symptoms and risk factors related to depression. hypothesis 2: youth who completed the sparx program were expected to experience an increase in factors related to resilience. a team of nunavut-based community mental health staff facilitated youth's participation in this remote pilot trial with 24 youth aged 13-18 across 11 communities in nunavut. these youth had been identified by community facilitators as showing low mood, depression, and/or significant levels of stress.


Eligibility criteria:
inclusion criteria: * one or more of the following: * low mood * negative affect * depressive presentations * significant levels of stress and: * sufficient english language comprehension to use and understand sparx exclusion criteria: none

Keywords: hopelessness catastrophizing rumination resilience
population based lighting study on older adults

Conditions: Lightning Strategies on Health; Circadian Rhythms Photoentrainment; Photoentrainment and Sleep; DLMO

Summary: the enlightenme project aims at collecting evidence about the impact of outdoor and indoor lighting on human health and wellbeing through the development and testing of innovative solutions and policies that will also counteract health inequalities in european cities. in particular, through an open-online urban lighting and health atlas, enlightenme will collect and systematize existing data and good practices on urban lighting and will perform an accurate analysis on the correlations among health, wellbeing, lighting and socio-economic factors in three pilot cities: bologna (italy), amsterdam (the netherlands), and tartu (estonia).

the enlightenme project aims at collecting evidence about the impact of outdoor and indoor lighting on human health and wellbeing through the development and testing of innovative solutions and policies that will also counteract health inequalities in european cities. in particular, through an open-online urban lighting and health atlas, enlightenme will collect and systematize existing data and good practices on urban lighting and will perform an accurate analysis on the correlations among health, wellbeing, lighting and socio-economic factors in three pilot cities: bologna (italy), amsterdam (the netherlands), and tartu (estonia). in this context, the enlightenme project will also include an interventional, multicenter, prospective, randomized, controlled, unblinded trial involving one target district, selected based on its artificial light characteristics, in the urban areas of each of one of the three pilot cities. within each target district, a random sample of individuals aged 65 years or older (intervention group) will be exposed to modifications in domestic indoor lighting and compared with a control group, living in the same target district, unexposed to domestic electric light modifications. at the same time, in a specific area of the target district, outdoor lighting will be modified by the local municipal authority. the hypothesis to be tested in this study is that light interventions may improve individual physical and mental health by affecting circadian entrainment, sleep pattern, and mood. thus, the study is aimed at providing evidence whether the planned change in electric light exposure at both urban public outdoor and domestic indoor lighting levels may impact on physical and mental health by improving photo-entrainment of circadian rhythms to the light-dark cycle

Eligibility criteria:
inclusion criteria: * living in the three selected cities within the target district chosen for the study * women and men * age 65 years or older * signing informed consent exclusion criteria: * lack of or inability to provide informed consent * lack of or inability to allow data collection over the course of the study